HK1164872A1 - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents

Disubstituted phthalazine hedgehog pathway antagonists

Info

Publication number
HK1164872A1
HK1164872A1 HK12105676.6A HK12105676A HK1164872A1 HK 1164872 A1 HK1164872 A1 HK 1164872A1 HK 12105676 A HK12105676 A HK 12105676A HK 1164872 A1 HK1164872 A1 HK 1164872A1
Authority
HK
Hong Kong
Prior art keywords
hedgehog pathway
pathway antagonists
disubstituted phthalazine
phthalazine hedgehog
disubstituted
Prior art date
Application number
HK12105676.6A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Bharvin Kumar Patel
Nee Takakuwa Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1164872A1 publication Critical patent/HK1164872A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12105676.6A 2009-06-19 2012-06-11 Disubstituted phthalazine hedgehog pathway antagonists HK1164872A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19
PCT/US2010/038568 WO2010147917A1 (en) 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
HK1164872A1 true HK1164872A1 (en) 2012-09-28

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105676.6A HK1164872A1 (en) 2009-06-19 2012-06-11 Disubstituted phthalazine hedgehog pathway antagonists

Country Status (36)

Country Link
US (2) US8273742B2 (lt)
EP (1) EP2443104B1 (lt)
JP (1) JP5596139B2 (lt)
KR (1) KR101389165B1 (lt)
CN (1) CN102459233B (lt)
AR (1) AR077014A1 (lt)
AU (1) AU2010260244B2 (lt)
BR (1) BRPI1011601A2 (lt)
CA (1) CA2764542C (lt)
CL (1) CL2011003147A1 (lt)
CO (1) CO6480932A2 (lt)
CR (1) CR20110658A (lt)
DK (1) DK2443104T3 (lt)
DO (1) DOP2011000386A (lt)
EA (1) EA019059B1 (lt)
EC (1) ECSP11011541A (lt)
ES (1) ES2409054T3 (lt)
HK (1) HK1164872A1 (lt)
HN (1) HN2011003139A (lt)
HR (1) HRP20130408T1 (lt)
IL (1) IL216599A (lt)
JO (1) JO2931B1 (lt)
MA (1) MA33363B1 (lt)
MX (1) MX2011014029A (lt)
MY (1) MY156667A (lt)
NZ (1) NZ596882A (lt)
PE (1) PE20121050A1 (lt)
PL (1) PL2443104T3 (lt)
PT (1) PT2443104E (lt)
SG (1) SG177289A1 (lt)
SI (1) SI2443104T1 (lt)
TN (1) TN2011000627A1 (lt)
TW (1) TWI385165B (lt)
UA (1) UA106755C2 (lt)
WO (1) WO2010147917A1 (lt)
ZA (1) ZA201108587B (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911618A2 (pt) * 2008-04-29 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de ftalazina dissubstituída.
ES2418479T3 (es) * 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
AU2009314288B2 (en) * 2008-11-17 2013-05-02 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
ES2392759T3 (es) 2008-11-17 2012-12-13 Eli Lilly And Company Piridazina tetrasustituida como antagonistas de la vía Hedgehog.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
EP2688565A1 (en) 2011-03-23 2014-01-29 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
WO2016196879A1 (en) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
CN109195593A (zh) 2016-03-15 2019-01-11 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
US11389434B2 (en) 2017-05-18 2022-07-19 Inserm Methods and pharmaceutical compositions for the treatment of mast cell diseases
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent
CN116349204A (zh) * 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (lt) * 1977-06-03 1981-03-07 Pfizer
ATE203534T1 (de) 1996-01-15 2001-08-15 Janssen Pharmaceutica Nv Angiogenesis hemmende pyridazinamine
AU768130B2 (en) 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
CA2455100C (en) * 2001-07-27 2013-05-28 Curis, Inc. Mediators of hedgehog signaling pathways,compositions and uses related thereto
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
ES2505091T3 (es) * 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
ES2392157T3 (es) 2007-09-07 2012-12-05 Amgen Inc. Piridazinas anilladas para el tratamiento de tumores dirigidos por señalización Hedgehog inapropiada
EA017918B1 (ru) * 2007-12-13 2013-04-30 СИЕНА БИОТЕК С.п.А. Антагонисты пути hedgehog и их терапевтические применения
BRPI0911618A2 (pt) * 2008-04-29 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de ftalazina dissubstituída.
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20110301162A1 (en) * 2008-08-04 2011-12-08 Amgen Inc. Aurora kinase modulators and methods of use
ES2418479T3 (es) 2008-11-03 2013-08-14 Eli Lilly And Company Antagonistas de la ruta erizo de ftalazinas disustituidas
ES2392759T3 (es) 2008-11-17 2012-12-13 Eli Lilly And Company Piridazina tetrasustituida como antagonistas de la vía Hedgehog.
AU2009314288B2 (en) 2008-11-17 2013-05-02 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
UA106755C2 (uk) 2014-10-10
PT2443104E (pt) 2013-05-07
ZA201108587B (en) 2013-05-29
CN102459233A (zh) 2012-05-16
CA2764542C (en) 2013-09-10
ECSP11011541A (es) 2012-01-31
US20120316174A1 (en) 2012-12-13
PL2443104T3 (pl) 2013-08-30
BRPI1011601A2 (pt) 2016-03-22
JO2931B1 (en) 2015-09-15
MX2011014029A (es) 2012-02-21
TW201113268A (en) 2011-04-16
DOP2011000386A (es) 2012-02-29
SI2443104T1 (sl) 2013-07-31
JP5596139B2 (ja) 2014-09-24
ES2409054T3 (es) 2013-06-24
CN102459233B (zh) 2014-07-02
EP2443104A1 (en) 2012-04-25
WO2010147917A1 (en) 2010-12-23
TWI385165B (zh) 2013-02-11
KR101389165B1 (ko) 2014-04-24
PE20121050A1 (es) 2012-08-09
MA33363B1 (fr) 2012-06-01
DK2443104T3 (da) 2013-05-06
TN2011000627A1 (en) 2013-05-24
IL216599A (en) 2015-09-24
NZ596882A (en) 2013-08-30
CR20110658A (es) 2012-02-20
HN2011003139A (es) 2013-07-29
HRP20130408T1 (en) 2013-06-30
CL2011003147A1 (es) 2012-07-20
CA2764542A1 (en) 2010-12-23
US9000023B2 (en) 2015-04-07
IL216599A0 (en) 2012-03-01
EA201270049A1 (ru) 2012-05-30
US20100324048A1 (en) 2010-12-23
US8273742B2 (en) 2012-09-25
EA019059B1 (ru) 2013-12-30
MY156667A (en) 2016-03-15
AR077014A1 (es) 2011-07-27
AU2010260244A1 (en) 2012-01-19
AU2010260244B2 (en) 2013-09-05
EP2443104B1 (en) 2013-04-17
SG177289A1 (en) 2012-02-28
KR20120024783A (ko) 2012-03-14
CO6480932A2 (es) 2012-07-16
JP2012530705A (ja) 2012-12-06

Similar Documents

Publication Publication Date Title
HRP20130408T1 (en) Disubstituted phthalazine hedgehog pathway antagonists
IL208211A0 (en) Disubstituted phthalazine hedgehog pathway antagonists
ZA201400310B (en) Solid dosage form
IL237391A0 (en) Pharmaceutical combination
GB0909680D0 (en) Dosage form
IL220091A0 (en) Pcsk9 antagonists
HRP20130527T1 (en) Disubstituted phthalazine hedgehog pathway antagonists
GB2473319B (en) Removable hydraulic-set packer
ZA201304617B (en) Orally disintegrating tablet
AP3250A (en) Tablets for combination therapy
EP2389068A4 (en) HEMGE OF THE HEDGEHOG SIGNAL PATH
ZA201304366B (en) Orally disintegrating tablet
ZA201200761B (en) Tablet
IL208953A0 (en) Pharmaceutical combination
AU330360S (en) Tablet
EP2612657A4 (en) TABLET WITH ORAL DISINTEGRATION
GB0920041D0 (en) Tablet
HUP0800414A2 (en) Pharmaceutical combination
GB0902665D0 (en) Dosage assembly
AU331949S (en) Tablet
AU330359S (en) Tablet
GB0910772D0 (en) Pharmaceutical
GB0918829D0 (en) Monitor

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200611